Stocks
JPMorgan Maintains Neutral Rating on Eyepoint Pharmaceuticals
Financial news provider MarketBeat reports that Eyepoint Pharmaceuticals (NASDAQ:EYPT) has maintained its 'neutral' rating from JPMorgan Chase & Co. in a research note issued on Monday.
This is not the first time the company's stock has received this rating; Cantor Fitzgerald also lowered shares of Eyepoint Pharmaceuticals from an 'overweight' rating to a 'neutral' rating in a report on Monday, according to MarketBeat.
Despite the 'neutral' ratings, Chardan Capital reaffirmed its 'buy' rating and issued a $65.00 price target on shares of Eyepoint Pharmaceuticals in a research note on Monday.